IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
IO Biotech (Nasdaq: IOBT) announced two poster presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas on November 8-10, 2024. The first poster will present updated data from the complete cohort (n=31) of PD-L1 high metastatic non-small cell lung cancer (NSCLC) patients in the Phase 2 basket trial of IO102-IO103 combined with pembrolizumab. The second poster will showcase new pre-clinical data for IO112, targeting Arginase 1. Dr. Jonathan W. Riess from UC Davis will present the NSCLC data, while IO Biotech scientists will present the IO112 data. Both posters will be displayed on November 9, 2024, at the George R. Brown Convention Center and will be available on IO Biotech's website.
IO Biotech (Nasdaq: IOBT) ha annunciato due presentazioni poster alla 39ª Conferenza Annuale della Society for Immunotherapy of Cancer (SITC 2024) che si terrà a Houston, Texas, dal 8 al 10 novembre 2024. Il primo poster presenterà dati aggiornati dal gruppo completo (n=31) di pazienti con carcinoma polmonare non a piccole cellule (NSCLC) metastatico ad alta espressione di PD-L1 nello studio clinico di Fase 2 che coinvolge IO102-IO103 in combinazione con pembrolizumab. Il secondo poster mostrerà nuovi dati preclinici su IO112, mirato all'Arginasi 1. Il Dr. Jonathan W. Riess dell'UC Davis presenterà i dati NSCLC, mentre gli scienziati di IO Biotech presenteranno i dati su IO112. Entrambi i poster saranno esposti il 9 novembre 2024, presso il George R. Brown Convention Center e saranno disponibili sul sito web di IO Biotech.
IO Biotech (Nasdaq: IOBT) anunció dos presentaciones en póster en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC 2024) en Houston, Texas, del 8 al 10 de noviembre de 2024. El primer póster presentará datos actualizados de la cohorte completa (n=31) de pacientes con cáncer de pulmón no microcítico (NSCLC) metastásico con alta expresión de PD-L1 en el ensayo de fase 2 de IO102-IO103 combinado con pembrolizumab. El segundo póster mostrará nuevos datos preclínicos para IO112, que tiene como objetivo la Arginasa 1. El Dr. Jonathan W. Riess de UC Davis presentará los datos de NSCLC, mientras que los científicos de IO Biotech presentarán los datos de IO112. Ambos pósters se exhibirán el 9 de noviembre de 2024 en el Centro de Convenciones George R. Brown y estarán disponibles en el sitio web de IO Biotech.
IO Biotech (Nasdaq: IOBT)는 2024년 11월 8일부터 10일까지 텍사스 주 휴스턴에서 열리는 39회 연례 암 면역 요법 학회(SITC 2024)에서 두 개의 포스터 발표를 진행한다고 발표했습니다. 첫 번째 포스터는 PD-L1 고발현 전이성 비소세포 폐암(NSCLC) 환자 전체 집단(n=31)의 최신 데이터를 IO102-IO103와 pembrolizumab 병용의 2상 바스켓 시험에서 발표할 것입니다. 두 번째 포스터는 Arginase 1을 표적하는 IO112에 대한 새로운 전임상 데이터를 전시할 것입니다. UC Davis의 Jonathan W. Riess 박사가 NSCLC 데이터를 발표하며, IO Biotech의 과학자들이 IO112 데이터를 발표할 예정입니다. 두 포스터 모두 2024년 11월 9일 조지 R. 브라운 컨벤션 센터에서 전시되며, IO Biotech 웹사이트에서도 확인하실 수 있습니다.
IO Biotech (Nasdaq: IOBT) a annoncé deux présentations de posters lors de la 39e Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (SITC 2024) à Houston, Texas, du 8 au 10 novembre 2024. Le premier poster présentera des données actualisées de la cohorte complète (n=31) de patients atteints de cancer du poumon non à petites cellules (NSCLC) métastatique à forte expression de PD-L1 dans l'essai de Phase 2 sur IO102-IO103 en combinaison avec pembrolizumab. Le second poster mettra en avant de nouvelles données précliniques pour IO112, ciblant l'Arginase 1. Le Dr. Jonathan W. Riess de l'UC Davis présentera les données sur le NSCLC, tandis que les scientifiques d'IO Biotech présenteront les données sur IO112. Les deux posters seront exposés le 9 novembre 2024 au George R. Brown Convention Center et seront disponibles sur le site web d'IO Biotech.
IO Biotech (Nasdaq: IOBT) hat zwei Posterpräsentationen auf dem 39. Jahresmeeting der Society for Immunotherapy of Cancer (SITC 2024) in Houston, Texas, vom 8. bis 10. November 2024, angekündigt. Das erste Poster wird aktualisierte Daten aus der vollständigen Kohorte (n=31) von PD-L1 hochgradigen metastasierten nicht-kleinzelligen Lungenkrebs (NSCLC) Patienten aus der Phase-2-Studie zu IO102-IO103 in Kombination mit Pembrolizumab präsentieren. Das zweite Poster wird neue präklinische Daten zu IO112 zeigen, das auf Arginase 1 abzielt. Dr. Jonathan W. Riess von der UC Davis wird die NSCLC-Daten präsentieren, während Wissenschaftler von IO Biotech die IO112-Daten vorstellen werden. Beide Poster werden am 9. November 2024 im George R. Brown Convention Center ausgestellt und auf der Website von IO Biotech verfügbar sein.
- Presentation of updated data from a Phase 2 trial in NSCLC patients
- Introduction of new pre-clinical data for pipeline candidate IO112
- None.
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024) taking place taking place in Houston, Texas on November 8-10, 2024.
The first abstract accepted for poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in the Company’s Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy (IOB-022/KN-D38). The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.
Poster Presentations
Title: A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)
Presenter: Jonathan W. Riess, MD, MS, UC Davis Comprehensive Cancer Center
Poster presentation number: 756
Date: Saturday, November 9, 2024
Location: Exhibit Halls AB - George R. Brown Convention Center
Times: Poster hall: 9:00 a.m. - 8:30 p.m. CDT; Poster session 12:00 – 1:30 p.m.; Poster reception 7:00-8:30 p.m.
Title: Immune modulating vaccine against arginase 1 controls tumor growth via modulation of tumor-associated macrophages
Presenters: Evelina Martinenaite, PhD, Senior Scientist, Translational Research, and Inés Lecoq, PhD, Scientist, Translational Research, IO Biotech
Poster presentation number: 1038
Date: Saturday, November 9, 2024
Location: Exhibit Halls AB - George R. Brown Convention Center
Times: Poster hall: 9:00 a.m. - 8:30 p.m. CDT; Poster session 12:00 – 1:30 p.m.; Poster reception 7:00-8:30 p.m.
The posters will be available on the “Posters & Publications” page of the IO Biotech website at the start of the meeting.
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About IOB-022/KN-D38 Phase 2 Solid Tumor Basket Trial
IOB-022/KN-D38 (NCT05077709) is a non-comparative, open-label trial to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in first-line advanced cancers in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Salutem
917-498-1967
Julie.Funesti@salutemcomms.com
FAQ
What will IO Biotech (IOBT) present at SITC 2024?
When and where will IO Biotech's (IOBT) posters be presented at SITC 2024?
What is the focus of IO Biotech's (IOBT) first poster presentation at SITC 2024?
Who will present IO Biotech's (IOBT) NSCLC data at SITC 2024?
